Key Developments: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.29USD
10:49am EST
Price Change (% chg)

$0.14 (+4.44%)
Prev Close
$3.15
Open
$3.18
Day's High
$3.31
Day's Low
$3.18
Volume
302,138
Avg. Vol
1,129,290
52-wk High
$5.58
52-wk Low
$1.31

Search Stocks

Latest Key Developments (Source: Significant Developments)

Geron Corp announces global strategic collaboration with Janssen to Develop and Commercialize Imetelstat
Thursday, 13 Nov 2014 04:15pm EST 

Geron Corp:Says it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses.Geron will receive an initial payment of $35 mln due after the applicable waiting periods under the Hart-Scott Rodino Act.And it is eligible to receive additional payments up to a potential total of $900 mln for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.  Full Article

Geron Corporation reports removal of partial clinical hold on Myelofibrosis IST
Thursday, 12 Jun 2014 05:00am EDT 

Geron Corporation:Says that U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis.The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat.In order to resolve the partial clinical hold, the investigator, Ayalew Tefferi of Mayo Clinic, Rochester, Minnesota, was required to provide follow-up information regarding reversibility of hepatotoxicity for all patients who received imetelstat in the Myelofibrosis IST.In its letter dated June 11, 2014, the FDA informed the investigator that it had completed the review of his complete response submission and concluded that the Myelofibrosis IST may proceed.  Full Article

Pomerantz LLP announces filing of class action against Geron Corporation and Certain Officers
Friday, 25 Apr 2014 05:27pm EDT 

Pomerantz LLP:Announces filing of a class action lawsuit against Geron Corporation and certain of its officers.Complaint alleges that persistent low-grade LFT abnormalities had been observed in the Phase 2 study of imetelstat in ET/PV patients.Says there was a potential risk of chronic liver injury following long-term exposure to imetelstat.Says that, as a result of the foregoing, Defendants' positive statements about the Company and the prospects for imetelstat lacked any reasonable basis and/or were materially false and misleading at all relevant times.  Full Article

Pomerantz LLP files class action against Geron Corp and certain officers
Friday, 28 Mar 2014 01:11pm EDT 

Pomerantz LLP:Files a class action lawsuit against Geron Corp and certain of its officers.Filed in United States District Court, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014.Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, prospects and performance.  Full Article

Ryan & Maniskas, LLP announces class action lawsuit against Geron Corp
Wednesday, 26 Mar 2014 05:03pm EDT 

Ryan & Maniskas, LLP:Files class action lawsuit in the united states district court for the Northern District of California on behalf of purchasers the securities of Geron Corp between June 16, 2013 and March 11, 2014, inclusive.Complaint charges Geron and certain of its executives with violations of federal securities laws. Specifically, the complaint alleges that Geron misrepresented and/or failed to disclose.Persistent low-grade liver function test abnormalities had been observed in the Phase 2 study of its drug imetelstat in essential thrombocythemia or polycythemia vera patients;.There was a high risk of potential chronic livery injury following long-term exposure to the drug, and.As a result of the foregoing, defendants' positive statements about the prospects for imetelstat lacked a reasonable basic and/or were materially false and misleading.  Full Article

Federman & Sherwood files securities class action lawsuit against Geron Corp
Tuesday, 18 Mar 2014 07:03pm EDT 

Federman & Sherwood:Say on March 14, a class action lawsuit was filed in the United States District Court for Northern District of California against Geron Corp.Complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating market price during class period.Class period is June 16, 2013 through March 11, 2014.Plaintiff seeks to recover damages on behalf of all Geron Corp shareholders who purchased common stock during class period outlined above, and are therefore a member of the class.  Full Article

Geron Corp announces the pricing of its public offering of common stock
Thursday, 30 Jan 2014 09:29am EST 

Geron Corp:Says the pricing of its previously announced underwritten public offering of 22,500,000 shares of its common stock, offered at a price to the public of $4.00 per share.Says the gross proceeds to Geron from this underwritten public offering are expected to be approximately $90 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron.Says the offering is expected to close on or about Feb. 4, subject to the satisfaction of customary closing conditions.Says Geron has also granted the underwriters an option to purchase up to an aggregate of 3,375,000 additional shares of its common stock offered in the public offering, exercisable for 30 days.Says all of the shares in the offering are to be sold by Geron.Says Geron intends to use the net proceeds from this public offering to fund research and development, including the company's planned Phase 2 clinical trial of imetelstat in myelofibrosis, and for working capital and general corporate purposes.Says BofA Merrill Lynch acted as sole book-running manager; Stifel acted as lead manager and Lazard Capital Markets LLC, Piper Jaffray & Co. and MLV & Co. acted as co-managers for the offering.  Full Article

Geron Corp announces proposed public offering of common stock
Wednesday, 29 Jan 2014 04:10pm EST 

Geron Corp:Intends to offer and sell shares of its common stock in an underwritten public offering.Expects to grant the underwriters an option to purchase up to an additional 15% of the shares of common stock offered in the public offering, exercisable for 30 days.Says all of the shares in the proposed offering are to be sold by Geron.Says offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Says BofA Merrill Lynch is acting as sole book-running manager; Stifel is acting as lead manager and Lazard Capital Markets LLC, Piper Jaffray & Co. and MLV & Co. LLC are acting as co-managers for the proposed offering.  Full Article

Geron Corp updates on cancer drug study - Reuters
Monday, 27 Jan 2014 11:55am EST 

Geron Corp:Says enrollment had ceased in an early stage trial of its blood cancer drug and that about 20 of 79 patients enrolled in the study had dropped out - Reuters.Geron did not say why the patients had dropped out of the trial or if the sponsor, the Mayo Clinic, had stopped the study prematurely.Says the patients in the study would continue to receive the drug and be monitored according to the study design.Says data from the 79 patients would be enough to support the drug's development.  Full Article

Geron Corp Completes Divestiture Of Stem Cell Assets
Tuesday, 1 Oct 2013 09:00am EDT 

Geron Corp announced the closing of the transaction to divest the Company's stem cell assets. On January 4, 2013, Geron entered into an Asset Contribution Agreement (the Agreement) with BioTime, Inc. and Asterias Biotherapeutics, Inc. (formerly known as BioTime Acquisition Corporation). The closing of the transaction was subject to certain approvals by BioTime's shareholders, the effectiveness of certain registration statements filed by BioTime and Asterias with the Securities and Exchange Commission (the SEC) with respect to the securities as contemplated by the Agreement, and other negotiated closing conditions. The closing of the transaction occurred on October 1, 2013. Under the terms of the Agreement, upon closing of the transaction, Geron contributed to Asterias intellectual property and tangible assets related to its discontinued human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. As consideration for Geron's contributions, Geron received approximately 6.5 million shares of Asterias Series A common stock.  Full Article

US STOCKS-Wall St flat after retail sales, UMich data

* Indexes: Dow off 0.01 pct, S&P up 0.05 pct, Nasdaq up 0.07 pct (Adds UMich data, Virgin America IPO)

Search Stocks